Procalcitonin Guided Antibiotic Use in Acute Respiratory Tract Infections (PARTI)-Study

This study has been completed.
Sponsor:
Collaborators:
Basel Institute of Clinical Epidemiology (BICE)
Brahms AG
Information provided by:
University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT00099840
First received: December 21, 2004
Last updated: April 24, 2007
Last verified: January 2006
  Purpose

Acute respiratory tract infections (ARTI) are among the most frequent reasons for seeking medical attention in primary care. Although from predominantly viral origin, ARTIs are the most important condition for the prescription of antibiotics (AB), mainly due to the difficulty in primary care to differentiate between viral and bacterial etiology. Unnecessary AB use increases drug expenditures, side effects and AB resistance. A novel approach is to guide AB use by procalcitonin (ProCT), since serum levels are elevated in bacterial infections but remain lower in viral infections and inflammatory diseases.

We aim to compare a strategy based on evidence-based guidelines with ProCT guided AB therapy in ARTIs with respect to outcome (days with restriction) and AB use. Patients presenting with ARTIs to primary care physicians and are intended to be treated with AB based on guidelines will be included and randomized 1:1 either to standard management or to the ProCT guided prescription of AB. All participating physicians will receive evidence-based guidelines for the management of patients with ARTIs. Patients with ARTI and in need of ABs by physicians’ clinical judgment and with informed consent will be randomized to ProCT plus guidelines ("ProCT group") versus only guidelines guided AB treatment ("control group"). In patients randomized to the ProCT group, the use of antibiotics will be more or less discouraged (<0.1 or <0.25 ug/L) or encouraged (>0.5 or >0.25 ug/L), respectively. A re-evaluation in patients with ProCT (<0.1 or <0.25 ug/L) after 6 to 24 hours is mandatory. All patients will be reassessed at day 3 and it is recommended to stop AB in the ProCT group as described above. Structured phone interviews at days 14 and 28 will be done in all patients from both groups.


Condition Intervention
Respiratory Tract Infections
Procedure: Procalcitonin guided antibiotic therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Procalcitonin Guided Antibiotic Use in Acute Respiratory Tract Infections in Primary Care - A Randomized Controlled Trial

Resource links provided by NLM:


Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • Days with restrictions from ARTI

Secondary Outcome Measures:
  • Rate of AB prescriptions
  • days with AB use
  • symptoms from ARTI
  • relapse rate from ARTI within 28 days
  • days with side effects from ABs and off work
  • cost-effectiveness

Estimated Enrollment: 400
Study Start Date: December 2004
Study Completion Date: April 2006
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years or older
  • ARTI of >1 and <28 days duration
  • In need of ABs based on the clinical judgment of the primary care physician

Exclusion Criteria:

  • Patients without informed consent
  • Not fluent in German
  • AB pretreatment in previous 28 days
  • Severe immune-suppression
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00099840

Locations
Switzerland
University Hospital
Basel, CH, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Basel Institute of Clinical Epidemiology (BICE)
Brahms AG
Investigators
Study Chair: Beat Muller, MD University Hospital, Basel, Switzerland
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00099840     History of Changes
Other Study ID Numbers: PARTIS
Study First Received: December 21, 2004
Last Updated: April 24, 2007
Health Authority: Switzerland: Swissmedic

Keywords provided by University Hospital, Basel, Switzerland:
common cold
pharyngitis
tonsillitis
rhinosinusitis
tracheo-bronchitis
otitis media
acute exacerbations of asthma
acute exacerbations of chronic pulmonary disease
community acquired pneumonia

Additional relevant MeSH terms:
Respiratory Tract Infections
Infection
Respiratory Tract Diseases
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antitubercular Agents

ClinicalTrials.gov processed this record on April 23, 2014